Funding Opportunities

The aim of this call is to validate (combinations of) already discovered, promising biomarkers that correlate with patient relevant outcomes or treatment responses and that can be used in daily clinical practice in the near future (TRL 5/6). Therefore, efforts are needed to set up collaborative, multidisciplinary studies with special attention to (combinations of) biomarkers that are potential candidates for clinical implementation. The focus of this call is to bring together the necessary expertise in the field of biomarker research and clinical care to reach the next developmental phase of the biomarker candidate(s) on their way to daily practice and to provide the appropriate framework and funding. 

• Timeline

With the Proof of Concept (PoC) programme KWF wants to stimulate the translation of impactful innovations to ensure they reach patients more quickly. The programme focuses on mapping out the path towards (clinical) application. The PoC application must be related to an ongoing or recently finished KWF project (up to 6 months after completion).

• Timeline 

With the Proof of Concept (PoC) programme KWF wants to stimulate the translation of impactful innovations to ensure they reach patients more quickly. The programme focuses on mapping out the path towards (clinical) application. The PoC application must be related to an ongoing or recently finished KWF project (up to 6 months after completion).

• Timeline 

This call is dedicated to basic research to uncover the underlying mechanisms that drive the onset, growth, and spread of cancer. Its aim is to address knowledge gaps, gain new scientific insights, and identify new leads and targets for preventive, diagnostic and therapeutic purposes. The call is intended for project proposals within the Basic research and Credentialing phases.

The aim of this call is to stimulate the further development of smart measurement technology to provide (early) diagnosis and monitoring of oncological patients in a minimally invasive manner and closer to home.

The aim of this call is to validate (combinations of) already discovered, promising biomarkers that correlate with patient relevant outcomes or treatment responses and that can be used in daily clinical practice in the near future. Therefore, efforts are needed to set up collaborative, multidisciplinary studies with special attention to (combinations of) biomarkers that are potential candidates for clinical implementation. The focus of this call is to bring together the necessary expertise in the field of biomarker research and clinical care to reach the next developmental phase of the biomarker candidate(s) on their way to daily practice and to provide the appropriate framework and funding. 

The PIPELINE call aims at the clinical development of new pharmaceuticals that originate from academic research and have the potential to substantially improve the treatment for cancer patients with unmet medical needs. Any type of pharmaceutical that is regulated as a medical product in the European Union is eligible.

The aim of this call is to contribute to an inclusive palliative care environment, where every patient, regardless of their cultural, religious or social background, receives respectful and high-quality care.

The long-term programme is meant to translate the most promising biomarker(s) into practice. Biomarker development will be supported until the biomarker is implemented on a national scale. This goal should be achieved within the shortest, yet realistic timeframe possible.